Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight
The Key Hypophosphatasia Companies in the market include - PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others.
DelveInsight's 'Hypophosphatasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypophosphatasia, historical and forecasted epidemiology as well as the Hypophosphatasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hypophosphatasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypophosphatasia Market Forecast
Some of the key facts of the Hypophosphatasia Market Report:
The Hypophosphatasia market size was valued at ~USD 880 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
The pipeline for Hypophosphatasia is not very robust, consisting of REC-01, ALXN1850, and others which are expected to launch during the forecast period [2022-2032]
According to DelveInsight's analysis, the diagnosed prevalent cases of Hypophosphatasia in the 7MM were estimated to be around 6,500 in 2023. This number is expected to rise by 2034 due to increased disease awareness among healthcare professionals and the general public worldwide.
In 2023, the US reported the highest diagnosed prevalence of hypophosphatasia among the 7MM, with approximately 6,000 cases. These numbers are expected to grow from 2024 to 2034, largely due to advancements in genetic testing that have enabled expanded newborn screening programs across the country.
Among the EU4 countries and the UK, Germany reported the highest number of diagnosed hypophosphatasia cases, with about 84 cases, followed by France with 69 cases, and the UK with 68 cases. These numbers are expected to increase by 2034, driven by a heightened focus on research and clinical trials for the disease.
In the UK, mild hypophosphatasia cases accounted for nearly 82%, moderate cases for 16%, and severe cases for 2% in 2023. The number of cases for each severity level is expected to rise by 2034.
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
The Hypophosphatasia epidemiology based on severity-specific cases analyzed that mild Hypophosphatasia was most prevalent in the US, followed by moderate and severe Hypophosphatasia
The Hypophosphatasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypophosphatasia pipeline products will significantly revolutionize the Hypophosphatasia market dynamics.
Hypophosphatasia Overview
Hypophosphatasia is defined as a rare, genetic metabolic disorder characterized by impaired mineralization of bones and teeth, according to National Organization for Rare Disorders (NORD). Defective mineralization results in bones that are soft and prone to fracture and deformity and it also leads to tooth loss. Depending on the specific form, it can be inherited in an autosomal recessive or dominant manner.
Hypophosphatasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypophosphatasia Epidemiology Segmentation:
The Hypophosphatasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving Hypophosphatasia epidemiology trends @ Hypophosphatasia Epidemiology Forecast
Hypophosphatasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypophosphatasia market or expected to get launched during the study period. The analysis covers Hypophosphatasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypophosphatasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypophosphatasia Therapies and Key Companies
Discover more about therapies set to grab major Hypophosphatasia market share @ Hypophosphatasia Treatment Market
Hypophosphatasia Market Strengths
Advancements in understanding the pathophysiology and genetics of Hypophosphatasia, thereby elucidating new targets for treatment
The approval of ERT by various regulatory authorities is a game changer, improving clinical manifestations, survival, and QoL
Hypophosphatasia Market Barriers
Developing specific biochemical biomarker-based assays with an increased understanding of differential diagnosis among physicians will lead to improvements in diagnosis, thus opening the windows of opportunity for new treatment options
There is a need for pharmacotherapeutic interventions for milder adult-onset of disease, which has little mortality and a high disease burden
Scope of the Hypophosphatasia Market Report
To know more about Hypophosphatasia companies working in the treatment market, visit @ Hypophosphatasia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hypophosphatasia Market Report Introduction
2. Executive Summary for Hypophosphatasia
3. SWOT analysis of Hypophosphatasia
4. Hypophosphatasia Patient Share (%) Overview at a Glance
5. Hypophosphatasia Market Overview at a Glance
6. Hypophosphatasia Disease Background and Overview
7. Hypophosphatasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypophosphatasia
9. Hypophosphatasia Current Treatment and Medical Practices
10. Hypophosphatasia Unmet Needs
11. Hypophosphatasia Emerging Therapies
12. Hypophosphatasia Market Outlook
13. Country-Wise Hypophosphatasia Market Analysis (2020–2034)
14. Hypophosphatasia Market Access and Reimbursement of Therapies
15. Hypophosphatasia Market Drivers
16. Hypophosphatasia Market Barriers
17. Hypophosphatasia Appendix
18. Hypophosphatasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
7 hours ago
- National Post
Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Article content CAMBRIDGE, Mass. — Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO). Article content 'David's extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,' said Geoff MacKay, President & CEO of Fable. 'We are excited to welcome David to our leadership team and for him to guide Fable's scientific strategy and innovative platform.' Article content Dr. Baker contributes deep expertise leading highly successful teams from across industry and academia. Prior to joining Fable, Dr. Baker was Head of Metabolism Bioscience for Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca plc. He was responsible for guiding the metabolism portfolio from target selection to Ph2b in diabetes, obesity, MASH and dyslipidemia. Article content Dr. Baker joins Fable at a pivotal time to oversee the company's scientific strategy from discovery through to IND and first-in-human studies. 'I'm thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,' said Dr. Baker. Article content About Fable Therapeutics, Inc. Article content Fable Therapeutics, Inc. (Fable) is a discovery-stage biotechnology company that aims to improve the lives of the millions of people living with metabolic diseases including obesity and related comorbidities. Founded by veteran biotech entrepreneurs and leading computational scientists and backed by top-tier venture capital firms, Fable is applying an industry-leading sequence- and structure-based machine learning platform to design and optimize next-generation protein-based therapeutics. Fable's pipeline of therapeutics addresses validated target biology that has not yet been fully exploited owing to technical and development hurdles that are addressed by Fable's ML-enabled protein design engine. Article content Backed by a 2024 $43.5M Series A investment co-led by Versant Ventures and DCVC, Fable is leading in the purposeful integration of biology and computation to solve complex medical challenges. Fable's aspiration is to write the next chapter of what protein-based therapeutics can do, both through its internal pipeline and research and development partnerships with pharmaceutical companies. Fable has locations in Cambridge, MA and Toronto, Canada. Article content Article content Article content
Cision Canada
5 days ago
- Cision Canada
Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025
Four Canadian nurses are among eleven global recipients of the International Nightingale award for excellence in MS nursing. The awards are presented by the International Organization of Multiple Sclerosis Nurses (IOMSN) with support from Merck KGaA, Darmstadt, Germany. MISSISSAUGA, ON, June 4, 2025 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce four Canadian nurses are among the recipients of the International Organization of Multiple Sclerosis Nurses (IOMSN) 2025 International Nightingale Award. The International Nightingale Award was launched in 2020 by IOMSN, with support from Merck KGaA, Darmstadt, Germany in celebration of the International Year of the Nurse and Midwife. "As a company dedicated to advancing multiple sclerosis care for over 25 years, we recognize that MS nurses play a vital role in providing care and support to patients. We are excited to collaborate with the IOMSN in this initiative, which celebrates nursing professionals and supports impactful projects that enhance patient outcomes," said Javed Alam, Managing Director of EMD Serono Canada. Having Canadian recipients of the International Nightingale Award recognizes the significance of MS nurse contributions to patient management and highlights the leadership role that Canadian nurses play on a global level. Shantha George, a community MS nurse practitioner in Edmonton, will receive $5,000 USD to support her Fight Back: Living Well with MS Program, an initiative that focuses on lifestyle management for mental health where patients learn tips to manage anxiety and depression including breathing techniques, drumming and yoga. Stephanie McLeod, a nurse practitioner at the Alberta Neurologic Centre in Calgary will receive $5,000 USD to support the development of a new program to enhance patient and family education, empowering those affected with MS with the knowledge and support they need. Lou-Anne Robertson, a registered nurse at the Central Alberta Multiple Sclerosis Clinic in Red Deer will receive $5,000 USD to support her efforts to raise awareness about the benefits of MS nurse certification for patient care and professional growth. Trudy Campbell, a nurse practitioner at the Halifax MS Clinic, Nova Scotia Health will receive $5,000 USD to support her work on evidence informed, holistic care pathways related to health promotion to support healthy aging for persons with MS. "Since 2020, IOMSN, EMD Serono and Merck KGaA Darmstadt, Germany have proudly celebrated 'The Lady with the Lamp', Florence Nightingale, who is a symbol of compassion, data-driven care, and nursing excellence. The IOMSN Nightingale Awards empower nurses to bring bold ideas to life, driving meaningful change for those living with MS" said Bonnie Blain, President of the IOMSN. " These awards not only recognize achievement but also inspire continued innovation and leadership in nursing. We are thrilled to partner again with Merck KGaA Darmstadt, Germany to present the 2025 International Nightingale Awards. I am honored to celebrate these Canadian Nightingale Recipients whose impactful work has the potential to improve the lives of their patients and resonate across their communities." The International Nightingale Award was awarded to eleven eligible candidates who live and work in countries outside of the United States. Each will receive funding of up to 5000 US Dollars for current projects that require ongoing and/or additional funding for the growth of the program; proposed time-limited projects; personal activities that will support the professional growth and development of an MS nursing professional; and/or nursing research in MS or a related field. About Multiple Sclerosis Multiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged. It is estimated that approximately 2.3 million people have MS worldwide. Canada has one of the highest rates of MS in the world with one in 385 people living with the disease. While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. The relapsing forms of MS are the most common type at the time of diagnosis. About the International Organization of Multiple Sclerosis Nurses (IOMSN) Founded on May 30, 1997, International Organization of Multiple Sclerosis Nurses (IOMSN) is the first and only international organization focusing solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing - the IOMSN supports nurses in their continuing effort to offer hope. The mission of the IOMSN is the establishment and perpetuation of a specialized branch of nursing in multiple sclerosis; to establish standards of nursing care in multiple sclerosis; to support multiple sclerosis nursing research; and to educate the health care community about multiple sclerosis; and to disseminate this knowledge throughout the world. The ultimate goal of the IOMSN is to improve the lives of all those persons affected by multiple sclerosis through the provision of appropriate healthcare services and to make hope happen! About EMD Serono, Canada EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Ontario. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Globe and Mail
28-05-2025
- Globe and Mail
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space. Both are making substantial investments in next-generation therapies such as cancer immunotherapies, treatments for respiratory conditions as well as GLP-1 drugs. With robust, research-driven pipelines and strong growth potential, they represent an intriguing comparison for investors considering large-cap pharmaceutical stocks. Though both companies have a diversified product profile, Lilly's largest segment is Cardiometabolic Health, which accounts for 72% of its total revenues. Lilly has a strong portfolio of medicines to treat diabetes and other cardiometabolic diseases. Its cardiometabolic business is its most successful business, particularly with the success of its popular GLP-1 drugs, Mounjaro for diabetes and Zepbound for obesity. On the other hand, Oncology is AstraZeneca's biggest segment, comprising around 41% of its total revenues. The company is working on strengthening its oncology product portfolio through label expansions of existing products and advancement of oncology pipeline candidates. Both Lilly and AstraZeneca are seeing strong sales and earnings growth. But which one is a better investment today? Let's take a closer look at their fundamentals, growth prospects and challenges to make an informed choice. The Case for Lilly Lilly boasts a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on cardiometabolic health, neuroscience, oncology and immunology, which are all high-growth areas with significant commercial potential. Despite being on the market for less than three years, Mounjaro and Zepbound became key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. We believe that increased uptake in outside U.S. markets and deeper penetration in the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years across different therapeutic areas like Omvoh, Jaypirca, Ebglyss and Kisunla (donanemab). Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025. Lilly is also making rapid pipeline progress in obesity, diabetes and cancer, with several key mid and late-stage data-readouts expected this year. Lilly is investing broadly in obesity and has several new molecules currently in clinical development. In terms of capital allocation, LLY returned $2.5 billion to shareholders in the first quarter via share repurchases and dividends. The board of directors of Lilly approved a new $15 billion stock buyback plan and also announced a 15% increase in its quarterly dividend in 2024. Lilly has its share of problems. Sales of its key medicine, Trulicity, are declining in the United States due to competitive dynamics, including Mounjaro switches and supply constraints. Prices of most of Lilly's products are declining in the United States. Potential competition in the GLP-1 diabetes/obesity market is another headwind. The stock also took a hit this month because CVS Caremark, a major pharmacy benefit manager ('PBM'), announced a partnership with rival Novo Nordisk NVO to make NVO's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. NVO also recently announced partnerships with telehealth providers Hims & Hers Health to offer Wegovy at a discounted price to cash-paying patients. Though Lilly's CEO, Dave Ricks does not expect CVS' decision to exclude Zepbound in favor of Wegovy to hurt Lilly's revenues, we believe it may hurt Zepbound's market share. The Case for AstraZeneca Headquartered in Cambridge, the United Kingdom, AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza, Calquence and Ultomiris. These drugs are driving the company's top line, backed by increasing demand trends. The company is confident that the growth will continue in 2025. Almost every new product it has launched in recent years has done well. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap are also expected to continue to contribute to top-line growth in 2025. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate $80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with nine new medicines already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026. AstraZeneca faces its share of challenges. The impact of Part D redesign hurt sales of AZN's older drugs, Tagrisso, Lynparza and Ultomiris, as well as newer drugs, Truqap and Wainua, in the United States in the first quarter of 2025, with the trend expected to continue through the rest of the year. AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in China in mid-2025, which can hurt sales of these drugs in the country. Pricing and competitive pressure in Europe and generic competition in some emerging markets are expected to hurt drug sales. In 2025, generic/biosimilar competition in the United States is expected to hurt sales of key drugs like Brilinta and Soliris. Sales in its Rare Disease segment are expected to be slower in 2025 than in 2024. As regards shareholders' returns, AstraZeneca intends to increase its annual dividend per share to $3.20 per share in 2025. How Do Estimates Compare for LLY & AZN? The Zacks Consensus Estimate for LLY's 2025 sales and EPS implies a year-over-year increase of 32.6% and 70.0%, respectively. EPS estimates for 2025 as well as 2026 have declined over the past 60 days. LLY Estimate Movement The Zacks Consensus Estimate for AstraZeneca's 2025 sales and EPS implies a year-over-year increase of 6.7% and 9.3%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days. AZN Estimate Movement Price Performance and Valuation of AZN & LLY Year to date, while LLY's stock has declined 5.7%, AstraZeneca's stock has risen 9.8%. The industry has declined 4.5% in the said time frame. Image Source: Zacks Investment Research Both Lilly and AZN are priced higher than the industry from a valuation standpoint. Lilly is more expensive than AstraZeneca, going by the price/earnings ratio. Lilly's shares currently trade at 28.31 forward earnings, higher than 15.13 for AZN. However, both AZN and LLY are trading at discounts to their 5-year mean. Image Source: Zacks Investment Research Lilly's dividend yield is 0.8%, while AZN's is much higher at around 2.9%. Lilly's return on equity of 85.5% is higher than AZN's 33.1%. LLY or AZN: Which is a Better Pick? Both Lilly and AstraZeneca have a Zacks Rank #3 (Hold), which makes choosing one stock a difficult task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Lilly is a good stock to have in one's portfolio, considering its diversified product and pipeline portfolio and robust growth prospects despite its expensive valuation. Lilly's tremendous success with Mounjaro and Zepbound has made it the largest drugmaker with a market cap of more than $650 billion. In 2025, Lilly expects to record revenues in the range of $58.0 billion to $61.0 billion, indicating an impressive 32% year-over-year growth. However, considering Lilly's several near-term challenges, AstraZeneca looks like a safer bet for short-term investors, given its price appreciation, cheaper valuation and robust growth prospects. Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. AstraZeneca expects core EPS to increase by a low double-digit percentage. Consistently rising estimates also indicate analysts' optimistic outlook for growth. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> AstraZeneca PLC (AZN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report
